Classes
Publications
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Some notes concerning the new anticoagulatn therapy2012 | First Faculty of Medicine
- Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk2011 | First Faculty of Medicine
- Commentary to Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: a therapeutic dilemma2010 | First Faculty of Medicine
- The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus2009 | First Faculty of Medicine, Faculty of Science
- Rosuvastatine2009 | First Faculty of Medicine
- Pravastatin and its place in therapy of dyslipidemia in 20102009 | First Faculty of Medicine
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Jistoty a nejistoty na křižovatkách současné medicíny2023 | First Faculty of Medicine
- Slibný perorální inhibitor PCSK9 ve vývoji2023 | First Faculty of Medicine
Loading network view...